Associated tags: Food, TK, Genomics, COVID-19 testing, COVID-19, Research, Dietary supplement, CLIA, Prophase, OTC, DNA, Gene, Nebula Genomics, Laboratory, PCR, Severe acute respiratory syndrome coronavirus 2, Chromosome, Pharmaceutical industry, Vaccine
Locations: DOYLESTOWN, PA, US, NY, EUROPE
Project,
FDA,
Sale,
Mayo Clinic,
Genomics,
Health,
Nebula Genomics,
Research,
Insurance,
Collection,
Water,
Consultant,
Genetic testing,
Development,
Public expenditure,
Automation,
DNA,
SNP,
Esophageal cancer,
Data,
Omicron,
Algorithm,
Three Months,
Patient,
CPT,
Acquisition,
Prophase,
Food,
Diagnosis,
Immunity,
Nebula,
HRSA,
Absorption,
COVID-19,
Engineering,
Medical device Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.
Key Points:
- The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
- Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
- Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
- Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.
Project,
FDA,
Sale,
Mayo Clinic,
Genomics,
Health,
Nebula Genomics,
Research,
Insurance,
Collection,
Water,
Consultant,
Genetic testing,
Development,
Public expenditure,
Automation,
DNA,
SNP,
Esophageal cancer,
Data,
Omicron,
Algorithm,
Three Months,
Patient,
CPT,
Acquisition,
Prophase,
Food,
Diagnosis,
Immunity,
Nebula,
HRSA,
Absorption,
COVID-19,
Engineering Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.
Key Points:
- The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
- Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
- Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
- Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.
Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST.
Key Points:
- Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST.
- Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion.
- To access the live presentation, please use the following information:
If you would like to book 1x1 investor meetings with ProPhase Labs, and to attend the Planet MicroCap Showcase: VEGAS 2024, please make sure you are registered here: https://planetmicrocapshowcase.com/signup
1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV
The Planet MicroCap Showcase: VEGAS 2024 website is available here: https://planetmicrocapshowcase.com/
If you can’t make the live presentation, all company presentations “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”: https://planetmicrocapshowcase.com/agenda
Project,
Cancer,
Genomics,
Whole genome sequencing,
Safety,
AI,
Esophageal cancer,
Nebula Genomics,
Genetics,
Machine learning,
WGS,
Doctor of Philosophy,
DNA,
SNP,
Therapy,
ADC,
Marker beacon,
Prophase,
NVIDIA,
Genome,
EAC,
Database,
Diagnosis,
CIO,
Biomarker,
Algorithm,
Spacecraft,
Medical device Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual’s entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company’s BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.
Key Points:
- Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI.
- "The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs.
- To support the computational demands of Project ZenQ-AI, ProPhase Labs is utilizing a dual-approach in technology.
- ProPhase Labs invites collaboration from across the scientific and medical communities to join in this groundbreaking initiative.
Retrieved on:
Wednesday, April 10, 2024
Mayo Clinic,
Cancer,
Genomics,
Hospital,
Esophageal cancer,
Proteomics,
Insurance,
Partnership,
Doctor of Philosophy,
Documentation,
Clinical professor,
Patient,
CPT,
Prophase,
Endoscopy,
EAC,
Health,
GERD,
Risk assessment,
Medical imaging Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.
Key Points:
- Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.
- Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future.
- ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics.
- Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies.
Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced that it has granted an inducement stock option to purchase up to 50,000 shares of the Company’s common stock to Lance Bisesar, who recently joined the Company as Controller.
Key Points:
- Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced that it has granted an inducement stock option to purchase up to 50,000 shares of the Company’s common stock to Lance Bisesar, who recently joined the Company as Controller.
- This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan.
- The option award will vest as follows, contingent upon continued service: 25% will vest on each of the next four anniversaries of the grant date.
- The options will have a strike price of $6.20 per share and will be exercisable for a period of 7 years.
Research,
WGS,
Automation,
Genomics,
Absorption,
Health,
Development,
Growth,
Exercise,
Nebula Genomics,
COVID-19,
Patient,
PMI,
RNA,
Sale,
Acquisition,
Public expenditure,
Food,
Engineering,
Insurance,
Protein,
Diagnosis,
RNA-Seq,
Omicron,
Prophase,
HRSA,
Whole genome sequencing,
Marketing,
FDA,
Genetic counseling,
Cryptocurrency Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023.
Key Points:
- With this significant repositioning completed, Nebula Genomics can now deliver low-cost, high-precision genomic diagnostics across North America and the global market.
- This agreement presents the possibility for significant expansion of its global footprint and paves the way for prospective future revenue streams.
- Research and development costs for the year ended December 31, 2023 and 2022 were $1.4 million and $0.7 million, respectively.
- Diluted earnings per share for the years ended December 31, 2023 and 2022 were $(0.98) and $1.02, respectively.
GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT.
Key Points:
- GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT.
- ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
- Investors interested in participating in this live event will need to register using the link below.
- After the event, a replay will be available on The Company’s Investor website.
Retrieved on:
Tuesday, February 20, 2024
Marie Cassidy,
Prophase,
Barrett's esophagus,
Patent,
Gastroenterology,
LDT,
Risk,
Cancer,
GI,
Mayo Clinic,
The Wall Street Journal,
Clinical professor,
Patient,
Carcinogenesis,
Clinical trial,
Genomics,
Esophageal cancer,
Plague This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
Key Points:
- This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
- If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024.
- Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.
- - The test has demonstrated molecular precision in excess of 99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.
Retrieved on:
Wednesday, February 14, 2024
Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has the potential to support and maintain immunity, which – if confirmed at the end of the clinical trial program – may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and Covid-19.
Key Points:
- Commercialization of Equivir anticipated after second trial is completed in Q2, 2024
Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its Equivir dietary supplement comprehensive trial.
- Each study enrolls 150 participants, randomly assigned to receive either Equivir or a placebo, with their health monitored over a 180-day period.
- Preliminary results are as follows:
Overall, in the initial 150 patient group there were approximately 46 incidences of upper respiratory viral infections.
- Equivir is being developed with plans to market as an OTC dietary supplement.
